The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Regorafenib (R) in advanced solitary fibrous tumor (SFT): Results from an exploratory phase II clinical study.
 
Silvia Stacchiotti
Honoraria - GlaxoSmithKline; Lilly; Novartis; PharmaMar
Consulting or Advisory Role - Bavarian Nordic; Bayer; Daiichi Sankyo; Deciphera; Epizyme; GlaxoSmithKline; Lilly; MaxiVax; Novartis; PharmaMar
Research Funding - Advenchen Laboratories (Inst); Amgen (Inst); Bayer (Inst); Blueprint Medicines; Daiichi Sankyo (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); SpringWorks Therapeutics (Inst)
Travel, Accommodations, Expenses - PharmaMar
 
Giacomo Giulio Baldi
Honoraria - Eisai; Lilly; PharmaMar
Consulting or Advisory Role - Aboutevents Srl; EditaMed; Eisai; GlaxoSmithKline; Lilly; Merck Sharp & Dohme; PharmaMar
Travel, Accommodations, Expenses - Lilly; Pfizer; PharmaMar
 
Salvatore Lo Vullo
No Relationships to Disclose
 
Carlo Morosi
No Relationships to Disclose
 
Francesca Gabriella Greco
No Relationships to Disclose
 
Paola Collini
No Relationships to Disclose
 
Marta Barisella
No Relationships to Disclose
 
Gianpaolo Dagrada
No Relationships to Disclose
 
Nadia Zaffaroni
No Relationships to Disclose
 
Alessandro Gronchi
Honoraria - Lilly; Novartis; Pfizer; PharmaMar
Consulting or Advisory Role - Bayer; Lilly; Nanobiotix; Novartis; Pfizer; PharmaMar; SpringWorks Therapeutics
Research Funding - PharmaMar (Inst)
Travel, Accommodations, Expenses - Nanobiotix; PharmaMar
 
Noemi Simeone
No Relationships to Disclose
 
Luigi Mariani
No Relationships to Disclose
 
Anna Maria Frezza
Research Funding - Advenchen Laboratories (Inst); Bayer (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Eisai (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst)
 
Paolo Giovanni Casali
Consulting or Advisory Role - Bayer
Research Funding - Advenchen Laboratories (Inst); Amgen/Dompé (Inst); Arog (Inst); Bayer (Inst); Blueprint Medicines (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Eisai (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst)